ExploRNA Therapeutics is a spin-off from the University of Warsaw, developing next generation mRNA technology for applications such as anti-cancer vaccines.
ExploRNA Therapeutics was founded by Professor Jacek Jemielity, Head of the Bio Organic Chemistry Laboratory at the Center of New Technologies CeNT at the University of Warsaw. Professor Jemielity’s first generation ‘cap modification’ mRNA technology was licensed in 2011 to the German company BioNTech.
According to the company, it’s next generation mRNA (with modified 5′ cap encoding neoantigens) is expected to have significantly improved benefits in stability, translational efficiency, and cost of synthesis.
ExploRNA’s two lead development programs will focus on tumor specific antigen vaccines and the expression of cytokines to promote cytotoxic T cells to eliminate tumor growth.
U-Ploid Biotechnologies aims to revolutionize IVF for Age-Related Infertility. Millions of women around the world face the emotional and financial toll of age-related infertility. As …
BioTryp Therapeutics is University of Cambridge spin-out biotechnology company that focuses on the development of small molecules to inhibit biofilm formation, which causes 80% of …
Bastion Therapeutics is a pre-clinical stage biotechnology company focused on developing best-in-class Treg cell therapies, which can target the root causes of inflammatory disorders and …
HOVANA is a digital biology company tackling translational dysfunction as a driver of serious diseases. Leveraging insights into cellular reprogramming, HOVANA is inventing a new …
Founded in 2022, Couragene is a biotechnology company developing first-in-class in vivo genetic therapies using its proprietary delivery platforms. The company's technology holds potential for …
Function Oncology is a precision medicine company advancing a CRISPR-powered personalized functional genomics platform to understand cancer in unprecedented and patient-specific detail. By moving beyond …
